12 research outputs found
A Complete Axiom System for Propositional Interval Temporal Logic with Infinite Time
Interval Temporal Logic (ITL) is an established temporal formalism for
reasoning about time periods. For over 25 years, it has been applied in a
number of ways and several ITL variants, axiom systems and tools have been
investigated. We solve the longstanding open problem of finding a complete
axiom system for basic quantifier-free propositional ITL (PITL) with infinite
time for analysing nonterminating computational systems. Our completeness proof
uses a reduction to completeness for PITL with finite time and conventional
propositional linear-time temporal logic. Unlike completeness proofs of equally
expressive logics with nonelementary computational complexity, our semantic
approach does not use tableaux, subformula closures or explicit deductions
involving encodings of omega automata and nontrivial techniques for
complementing them. We believe that our result also provides evidence of the
naturalness of interval-based reasoning
Deep RNA Sequencing Reveals Hidden Features and Dynamics of Early Gene Transcription in Paramecium bursaria Chlorella Virus 1
Responses to increases in temperature of heterotrophic micro-organisms in soils from the maritime Antarctic
Leaf litter diversity alters microbial activity, microbial abundances, and nutrient cycling in a subtropical forest ecosystem
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients
Aim To assess the safety and tolerability of adjuvant subcutaneous trastuzumab (Herceptin® SC, H SC), delivered from an H SC Vial via hand-held syringe (Cohort A) or single-use injection device (Cohort B), with or without chemotherapy, for human epidermal growth factor receptor 2 (HER2)-positive stage I to IIIC early breast cancer (EBC) in the phase III SafeHer study (NCT01566721). Methods Patients received 600 mg fixed-dose H SC every 3 weeks for 18 cycles. The chemotherapy partner was at the investigators' discretion (H SC monotherapy was limited to ≤10% of the population). Data from the first H SC dose until 28 days (plus a 5-day window) after the last dose are presented. Results are descriptive. Results In the overall population, 2282/2573 patients (88.7%) experienced adverse events (AEs). Of the above, 128 (5.0%) patients experienced AEs leading to study drug discontinuation; 596 (23.2%) experienced grade ≥ 3 AEs and 326 (12.7%) experienced serious AEs. Grade ≥ 3 cardiac disorders were reported in 24 patients (0.9%), including congestive heart failure in eight (0.3%). As expected, the AE rates varied according to the timing of chemotherapy in both cohorts, with higher rates in concurrent versus sequential chemotherapy subgroups. In the concurrent chemotherapy subgroup, AEs were more common during the actual period of concurrent chemotherapy compared with the period when patients did not receive concurrent chemotherapy. Conclusion SafeHer confirms the safety and tolerability of the H SC 600 mg fixed dose for 1 year (every 3 weeks for 18 cycles) as adjuvant therapy with concurrent or sequential chemotherapy for HER2-positive EBC. These primary analysis results are consistent with the known safety profile for intravenous H and H SC